CRISPR Therapeutics AG
NASDAQ:CRSP
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
44.62
89.12
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CRSP stock under the Base Case scenario is 119.73 USD. Compared to the current market price of 47.88 USD, CRISPR Therapeutics AG is Undervalued by 60%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
CRISPR Therapeutics AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CRSP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
CRISPR Therapeutics AG
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
CRISPR Therapeutics AG
Balance Sheet Decomposition
CRISPR Therapeutics AG
Current Assets | 1.9B |
Cash & Short-Term Investments | 1.9B |
Other Current Assets | 8.2m |
Non-Current Assets | 312.2m |
PP&E | 284.8m |
Other Non-Current Assets | 27.4m |
Current Liabilities | 89.8m |
Accounts Payable | 15.6m |
Accrued Liabilities | 64.1m |
Other Current Liabilities | 10.1m |
Non-Current Liabilities | 226.7m |
Other Non-Current Liabilities | 226.7m |
Earnings Waterfall
CRISPR Therapeutics AG
Revenue
|
202.8m
USD
|
Operating Expenses
|
-535.2m
USD
|
Operating Income
|
-332.4m
USD
|
Other Expenses
|
92.8m
USD
|
Net Income
|
-239.6m
USD
|
Free Cash Flow Analysis
CRISPR Therapeutics AG
USD | |
Free Cash Flow | USD |
CRSP Profitability Score
Profitability Due Diligence
CRISPR Therapeutics AG's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
CRISPR Therapeutics AG's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
CRSP Solvency Score
Solvency Due Diligence
CRISPR Therapeutics AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
CRISPR Therapeutics AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRSP Price Targets Summary
CRISPR Therapeutics AG
According to Wall Street analysts, the average 1-year price target for CRSP is 81.43 USD with a low forecast of 30.3 USD and a high forecast of 208.95 USD.
Dividends
Current shareholder yield for CRSP is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CRSP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
CRISPR Therapeutics AG operates as a gene editing company. The company is headquartered in Zug, Zug and currently employs 473 full-time employees. The company focuses on the development of transformative gene-based medicines for serious diseases. The firm develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The firm has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The firm has business operations in London and the United Kingdom, as well as research and development operations in the United States.
Officers
The intrinsic value of one CRSP stock under the Base Case scenario is 119.73 USD.
Compared to the current market price of 47.88 USD, CRISPR Therapeutics AG is Undervalued by 60%.